Premium
Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting
Author(s) -
Seaquist Elizabeth R.,
Dulude Hélène,
Zhang Xiaotian M.,
RabasaLhoret Remi,
Tsoukas George M.,
Conway James R.,
Weisnagel Stanley J.,
Gerety Gregg,
Woo Vincent C.,
Zhang Shuyu,
Carballo Dolorès,
Pradhan Sheetal,
Piché Claude A.,
Guzman Cristina B.
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13278
Subject(s) - medicine , adverse effect , prospective cohort study , continuous glucose monitoring , type 2 diabetes , type 1 diabetes , population , diabetes mellitus , glucagon , anesthesia , insulin , endocrinology , environmental health
In the present multicentre, open‐label, prospective, phase III study, we evaluated the real‐world effectiveness and ease of use of nasal glucagon (NG) in the treatment of moderate/severe hypoglycaemic events (HEs) in adults with type 1 diabetes (T1D). Patients and caregivers were taught how to use NG (3 mg) to treat moderate/severe HEs, record the time taken to awaken or return to normal status, and measure blood glucose (BG) levels over time. Questionnaires were used to collect information about adverse events and ease of use of NG. In the efficacy analysis population, 69 patients experienced 157 HEs. In 95.7% patients, HEs resolved within 30 minutes of NG administration. In all the 12 severe HEs, patients awakened or returned to normal status within 15 minutes of NG administration without additional external medical help. Most caregivers reported that NG was easy to use. Most adverse events were local and of low to moderate severity. In this study, a single, 3‐mg dose of NG demonstrated real‐life effectiveness in treating moderate and severe HEs in adults with T1D. NG was well tolerated and easy to use.